Coherus Oncology's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.16.
During the past 3 years, the average EBIT per Share Growth Rate was 22.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Coherus Oncology's EBIT per Share or its related term are showing as below:
FRA:8C5'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.4 Med: 17.9 Max: 22.4
Current: 22.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Coherus Oncology was 22.40% per year. The lowest was -40.40% per year. And the median was 17.90% per year.
FRA:8C5's 3-Year EBIT Growth Rate is ranked better than 59.68% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:8C5: 22.40
Coherus Oncology's EBIT for the
three
months ended in Mar. 2026 was €-30.06 Mil.
Coherus Oncology (FRA:8C5) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Coherus Oncology EBIT per Share Related Terms
Coherus Oncology EBIT per Share Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a EBIT per Share of €-1.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #473 out of 1173 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Coherus Oncology's EBIT per Share too high?
Coherus Oncology's current EBIT per Share is €-1.16. Based on the distribution chart, Coherus Oncology ranks #473 out of 1173 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's EBIT per Share compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #473 out of 1173 companies for EBIT per Share. This puts Coherus Oncology in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current EBIT per Share is €-1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €1.40 — trading 118.6% above its estimated fair value. The current EBIT per Share is €-1.16. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current EBIT per Share is €-1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.40 is trading 118.6% above its estimated GF Value™ of €0.64.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
EBIT per Share: €-1.16
GF Value™: €0.64 vs. price of €1.40 (118.6% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
